EndoExpertHub

R. Michael Tuttle, MD is a Professor of Medicine at Weill Medical College of Cornell University and serves as Chief of the Endocrinology Service at Memorial Sloan Kettering Cancer Center in New York City. His clinical practice is devoted entirely to the evaluation and management of patients with thyroid cancer, with a particular emphasis on cases involving aggressive disease and complex management challenges. R. Michael Tuttle, MD earned his medical degree from the University of Louisville School of Medicine and completed his residency at Dwight David Eisenhower Army Medical Center, followed by a fellowship at Madigan Army Medical Center. He is board-certified in Endocrinology and Metabolism. R. Michael Tuttle, MD's research is centered on the management of thyroid cancer, with particular focus on individualized risk stratification and the rational tailoring of therapy to patient-specific outcomes. He designed and validated the first real-time risk assessment model for thyroid cancer management, in which individual risk estimates are updated over time based on response to initial therapy. His ongoing investigations address the risk of recurrence and disease-specific mortality in individual patients, the appropriate role of active surveillance in low-risk papillary thyroid cancer, and the application of minimalistic management strategies to reduce overtreatment. His earlier clinical studies also helped define the role of recombinant human TSH as an adjuvant for radioactive iodine therapy in both low- and high-risk patients, including those with radioactive iodine-avid distant metastases. In addition to his clinical and research contributions, R. Michael Tuttle, MD is a prolific academic author with more than 460 research works and over 54,000 citations to his credit. He has been repeatedly recognized by Castle Connolly as one of America's Top Doctors, with distinctions spanning more than a decade, and is consistently listed among New York Metro Area's Top Doctors.

Abhimanyu Garg, M.D. is a Professor of Internal Medicine in the Division of Endocrinology at UT Southwestern Medical Center in Dallas, Texas, where he also serves as Director of Metabolic Diseases in the Center for Human Nutrition, Director of the Nutrition and Metabolic Diseases Fellowship Program, and holder of the Distinguished Chair in Human Nutrition Research. His clinical practice is devoted to the evaluation and management of patients with lipodystrophy, lipid metabolism disorders, and related metabolic diseases. Abhimanyu Garg, M.D. earned his medical degree and completed his residency in internal medicine at the All India Institute of Medical Sciences. He subsequently completed fellowship training in endocrinology and metabolism at the University of Alabama at Birmingham and at UT Southwestern, where he joined the faculty in 1988. Abhimanyu Garg, M.D. is widely regarded as the leading global authority on lipodystrophy research and treatment, having devoted nearly three decades to advancing the understanding and management of these rare disorders. He was the first investigator to evaluate leptin as a therapeutic option for lipodystrophy through a clinical trial launched at UT Southwestern in 2000, work that directly contributed to the FDA's 2014 approval of metreleptin for the treatment of generalized lipodystrophy. His ongoing research focuses on whether leptin therapy can improve metabolic outcomes in hypoleptinemic patients with partial lipodystrophies. In addition to his clinical and research contributions, Abhimanyu Garg, M.D. is a recipient of the Jean D. Wilson, M.D. Award for excellence in scientific mentorship in the Division of Endocrinology and Metabolism at UT Southwestern. He holds membership in the American Diabetes Association, the Endocrine Society, the American Society of Human Genetics, and the Association of Specialty Professors, among other professional organizations.

Daniel A. Dumesic, MD is a Professor and Division Chief of Reproductive Endocrinology and Infertility in the Department of Obstetrics and Gynecology at the University of California, Los Angeles. He is affiliated with Ronald Reagan UCLA Medical Center and UCLA Medical Center-Santa Monica, where his clinical practice centers on female infertility, in vitro fertilization, and polycystic ovary syndrome. He serves as a member of the Practice Committee of the American Society for Reproductive Medicine and is a Fellow of the American College of Obstetricians and Gynecologists and a member of the Endocrine Society. Daniel A. Dumesic, MD earned his medical degree from the University of Wisconsin School of Medicine and Public Health and completed his residency in Obstetrics and Gynecology at the University of Minnesota. He went on to complete a fellowship in Reproductive Endocrinology and Infertility at the University of California, San Francisco. He is board-certified by the American Board of Obstetrics and Gynecology in both Obstetrics and Gynecology and Reproductive Endocrinology and Infertility. Daniel A. Dumesic, MD's research focuses on the mechanistic and clinical dimensions of female reproductive disorders, with particular emphasis on polycystic ovary syndrome and its metabolic consequences. His investigations have examined the role of androgen excess in adipogenic dysfunction in PMOS, the paracrine regulation of oocyte competence, and the interplay between body fat distribution, cortisol, and testosterone in affected women. He has served as Principal Investigator on multiple NIH-funded and university-awarded projects and has published over 200 papers in the field of reproductive endocrinology. His work spans both human clinical studies and translational research, and he has been an active contributor to NIH research study sections and committees throughout his career. In addition to his research, Daniel A. Dumesic, MD is widely recognized for his contributions to the field. He has received the Mayo Award for Excellence in Leadership and is a nine-time recipient of the American Society for Reproductive Medicine's Star Award, given for more than ten years of sustained contributions to research. Stanford University has ranked him within the top 2% of all scientists in clinical medicine globally. He has also been honored with the Ricardo Azziz Distinguished Researcher Award from the Androgen Excess and PMOS Society and has been named a Top Doctor in Southern California.